Business
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
DURHAM, N.C., January 12, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points.
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6af1b4627a1b5c423d236ad92f5ad715"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bhXNal7l595_Y5jlxOXREw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6af1b4627a1b5c423d236ad92f5ad715","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ucqh8M2khXsCKY53193O0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6af1b4627a1b5c423d236ad92f5ad715","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, 2025, anticipated to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., January 12, 2026--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points.","length":504,"tagName":"p"},{"type":"text","content":""We continue to make steady, disciplined progress across our clinical-stage programs," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "With multiple dosing cohorts underway in our global Phase 1/2a ELIMINATE-B trial, our first-in-class gene editing approach for DMD entering the clinic in early 2026, and cash runway through 2028, we expect continued operational e...